State of Alaska Department of Revenue Has $2.20 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

State of Alaska Department of Revenue lessened its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,112 shares of the company’s stock after selling 168 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.06% of Prestige Consumer Healthcare worth $2,195,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Martingale Asset Management L P grew its holdings in shares of Prestige Consumer Healthcare by 0.4% during the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after purchasing an additional 140 shares in the last quarter. Horizon Kinetics Asset Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 4.8% during the 3rd quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock worth $234,000 after purchasing an additional 150 shares in the last quarter. OLD National Bancorp IN lifted its position in shares of Prestige Consumer Healthcare by 4.4% during the 3rd quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock worth $287,000 after buying an additional 168 shares during the period. Huntington National Bank lifted its position in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after buying an additional 220 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Up 0.3 %

Shares of PBH opened at $87.29 on Tuesday. The stock has a fifty day moving average price of $79.23 and a two-hundred day moving average price of $75.51. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.10 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a 52-week low of $62.35 and a 52-week high of $88.36. The company has a market cap of $4.31 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

PBH has been the subject of several analyst reports. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $92.50.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.